MASLD as a Diurnal Metabolic Disease: Nocturnal Insulin Resistance and Persistent Hepatic Vulnerability
The Core Claim Lacks Direct Evidence Support
The assertion that MASLD is fundamentally a "diurnal metabolic disease driven by nocturnal insulin resistance" is not substantiated by the current guideline or research evidence provided. While insulin resistance is unequivocally central to MASLD pathophysiology, the available literature does not characterize this as a specifically nocturnal or circadian phenomenon, nor does it describe hepatic vulnerability as persisting "at night" despite weight loss 1, 2, 3.
What the Evidence Actually Shows About Insulin Resistance in MASLD
Insulin Resistance Is Central but Not Time-Specific
Insulin resistance drives MASLD through continuous metabolic dysfunction, not through a diurnal pattern. The liver exhibits "selective insulin resistance" where insulin fails to suppress gluconeogenesis but paradoxically continues to stimulate de novo lipogenesis (DNL), creating a dual metabolic defect that promotes both hyperglycemia and hepatic steatosis 1.
The mechanism involves defective insulin/IRS/AKT signaling that impairs glucose metabolism while lipogenesis remains unrestrained, leading to progressive fat accumulation in hepatocytes 1.
Peripheral insulin resistance in adipose tissue and muscle amplifies hepatic lipid deposition by increasing free fatty acid flux to the liver, independent of any circadian timing 1, 2.
The Only Temporal Recommendation: Late-Evening Snacks in Cirrhosis
Guidelines recommend a late-evening snack specifically for cirrhotic or sarcopenic MASLD patients to reduce overnight fasting duration and preserve muscle mass, but this addresses sarcopenia prevention—not a fundamental diurnal vulnerability of the liver itself 4.
This nutritional strategy aims to provide sustained amino acid availability during the prolonged overnight fast, which is particularly harmful in patients with impaired hepatic synthetic function and accelerated muscle catabolism 4.
Why Hepatic Vulnerability Persists Despite Weight Loss
Weight Loss Improves but Does Not Eliminate Metabolic Dysfunction
Weight reduction of 7–10% achieves MASH resolution and fibrosis regression in many patients, but this does not universally reverse the underlying insulin resistance or eliminate cardiometabolic risk factors 4, 5.
MASLD exhibits substantial pathophysiologic heterogeneity: some patients have predominantly adipose-driven disease, others have primary hepatic insulin resistance, and still others have genetic predispositions (e.g., PNPLA3 variants) that persist regardless of weight change 2.
Even after significant weight loss, residual insulin resistance, dysfunctional adipose tissue, subclinical inflammation, and altered hepatokine secretion can maintain hepatic vulnerability to metabolic stress 2, 6.
The Liver Remains Metabolically Fragile
MASLD is not merely a consequence of obesity but a manifestation of systemic metabolic dysfunction involving dysregulated glucose metabolism, atherogenic dyslipidemia, hypertension, and chronic low-grade inflammation—factors that do not fully normalize with weight loss alone 7, 2, 6.
The liver continues to face increased fatty acid delivery, impaired mitochondrial β-oxidation, endoplasmic reticulum stress, and oxidative injury even after steatosis improves, particularly if cardiometabolic risk factors remain inadequately controlled 5, 2, 8.
Hepatic stellate cell activation and fibrogenesis pathways, once triggered, may persist despite reduction in hepatic fat content, explaining why some patients progress to cirrhosis despite weight loss 5.
Common Pitfalls in Understanding MASLD Pathophysiology
Do not conceptualize MASLD as a purely hepatic disease: it is a systemic cardiometabolic disorder in which the liver is one affected organ among many (cardiovascular system, kidneys, pancreas) 9, 2, 6.
Do not assume weight loss alone is curative: while it is the cornerstone of therapy, pharmacologic management of diabetes, dyslipidemia, and hypertension—plus MASH-targeted agents like resmetirom or GLP-1 agonists—are often necessary to halt progression 4, 5, 10.
Do not overlook the role of genetic and epigenetic factors: these contribute to treatment response heterogeneity and explain why some lean individuals develop severe MASH while some obese individuals remain protected 2.
Practical Clinical Framework
Address Insulin Resistance Continuously, Not Diurnally
Optimize glycemic control with GLP-1 receptor agonists (semaglutide, liraglutide, tirzepatide) or SGLT2 inhibitors (empagliflozin, dapagliflozin), which improve hepatic steatosis, inflammation, and fibrosis while providing cardiovascular and renal protection 4, 6, 3, 10.
Continue metformin in patients with compensated cirrhosis (eGFR >30 mL/min), as discontinuation increases mortality despite its lack of direct histologic benefit 4.
Recognize That Weight Loss Is Necessary but Insufficient
Target 7–10% body-weight reduction through Mediterranean diet, ≥150 min/week moderate-intensity exercise, and behavioral support 4, 5.
Add resmetirom for non-cirrhotic MASH with fibrosis F2–F3 if lifestyle and metabolic optimization do not achieve adequate disease control 4, 5, 10.
Consider bariatric surgery for BMI ≥40 kg/m² or ≥35 kg/m² with comorbidities, as it provides durable metabolic improvement and histologic MASH resolution 4, 5.
Monitor for Persistent Cardiometabolic Risk
Reassess fibrosis stage annually with FIB-4 and elastography in patients with F2–F3 disease, recognizing that non-invasive tests track progression better than treatment response 4.
Screen for cardiovascular disease, chronic kidney disease, and extrahepatic malignancies, as these—not liver failure—are the leading causes of death in MASLD patients 2, 6, 8.